Compare SANM & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANM | IOVA |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 2.1B |
| IPO Year | 1994 | 2008 |
| Metric | SANM | IOVA |
|---|---|---|
| Price | $126.28 | $4.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $160.00 | $9.11 |
| AVG Volume (30 Days) | 610.3K | ★ 15.8M |
| Earning Date | 04-27-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.07 | ★ 14.84 |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $7,890,475,000.00 | N/A |
| Revenue This Year | $75.95 | $49.14 |
| Revenue Next Year | $12.89 | $51.69 |
| P/E Ratio | $142.71 | ★ N/A |
| Revenue Growth | ★ 16.78 | N/A |
| 52 Week Low | $63.67 | $1.64 |
| 52 Week High | $185.29 | $5.63 |
| Indicator | SANM | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 36.09 | 54.58 |
| Support Level | $123.17 | $1.99 |
| Resistance Level | $163.34 | $4.34 |
| Average True Range (ATR) | 7.31 | 0.48 |
| MACD | -2.11 | 0.06 |
| Stochastic Oscillator | 16.01 | 42.91 |
Sanmina Corp is a provider of integrated manufacturing solutions, components, and after-market services to original equipment manufacturers in the communications networks, storage, industrial, defense, and aerospace end markets. The operations are managed as two businesses: Integrated Manufacturing Solutions, which consists of printed circuit board assembly and represents a majority of the firm's revenue; and Components, Products, and Services, which includes interconnect systems and mechanical systems. The firm generates revenue mainly in the United States, China, and Mexico, but has a presence around the world.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.